{"acf2caae-0773-4eb2-bb10-57a01b19e200": "hsatter", "b36780e0-cb72-4402-8bda-d3fd3a8925b0": "This is a FDA news release on the approval of Recarbrio (a combination of imipenem-cilastatin and relebactam) to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP) in patients 18 years of age and older. Recarbrio was previously FDA-approved to treat patients with complicated urinary tract infections and complicated intra-abdominal infections who have limited or no alternative treatment options."}